BTMD

Biote Corp. 10-Q Summary: Q2 2025

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Biote Corp. (BTMD) operates as a single segment business providing the "Biote Method," a platform for hormone optimization using bioidentical hormone replacement pellet therapy. The company trains physicians, provides practice management software, and sells bioidentical hormone pellets and dietary supplements. As of June 30, 2025, the company had approximately 33.3 million shares of Class A common stock outstanding.

Key Financial Metrics

Note: Debt figures represent the gross term loan balance. Share repurchase liabilities include both current and non-current portions.

Material Changes vs. Prior Period

• Profitability Turnaround: The company reported a net income of $3.9 million for Q2 2025, a significant improvement from a net loss of $10.4 million in Q2 2024. This was driven by a $12.1 million reduction in the loss from the change in fair value of earnout liabilities.
• Revenue Composition: While total revenue remained relatively flat (-0.6% QoQ), the mix shifted. Pellet procedure revenue decreased by $3.2 million due to clinic attrition and lower volumes. Conversely, dietary supplement revenue increased by $2.5 million, aided by a shift to an Amazon e-commerce platform.
• Cost Management: Cost of revenue decreased by 9.7% year-over-year, largely due to cost savings from the vertical integration of Asteria Health (acquired in 2024). SG&A expenses decreased by 12.2% due to lower commissions, stock compensation, and legal fees, partially offset by a $0.6 million restructuring charge.
• Liquidity: Cash and cash equivalents declined by $19.7 million year-to-date, primarily due to $25.1 million in payments toward share repurchase liabilities and $3.1 million in term loan principal repayments.

Guidance, Outlook, and Risks

• Management Commentary: Management highlighted the successful integration of Asteria Health and the strategic shift of dietary supplement sales to Amazon. A CEO transition occurred on February 1, 2025, with Bret Christensen replacing Teresa S. Weber. A workforce reduction of approximately 7.2% was completed in Q2 to improve efficiency.
• Legal Contingencies:
  • Right Value Litigation: Settled for $5.0 million; $3.5 million paid in Q2, with $1.5 million remaining as a liability.
  • Cindy Latch Litigation: A temporary injunction regarding the use of her likeness was reversed by the Court of Appeals in April 2025. Trial is scheduled for April 2026.
  • Dr. Gary Donovitz Litigation: Ongoing disputes regarding name, image, and likeness rights. A temporary restraining order remains in force in Delaware, precluding prosecution in Texas pending further court motions.
• Internal Controls: The company disclosed a material weakness in internal control over financial reporting that has not been remediated as of June 30, 2025. This relates to insufficient technical accounting personnel and IT general controls.
• Tax Legislation: The company is evaluating the impact of the "One Big Beautiful Bill Act" signed on July 4, 2025, on its deferred tax assets and effective tax rate.

Investor Verification Checklist

• Remediation of Material Weakness: Verify the timeline and specific steps management is taking to remediate the internal control material weakness, as this impacts financial reporting reliability.
• Share Repurchase Liability: Confirm the remaining balance ($45.8 million) and the schedule for future payments, as this represents a significant cash outflow obligation.
• Legal Settlements: Monitor the status of the Cindy Latch and Dr. Donovitz litigations for potential future cash settlements or operational restrictions on marketing.
• Revenue Mix Sustainability: Assess whether the growth in dietary supplement revenue can sustainably offset the decline in pellet procedure revenue.
• Debt Covenants: Verify continued compliance with the Truist Credit Agreement covenants (Net Leverage Ratio ≤ 3.75:1.00 and Fixed Charge Coverage Ratio ≥ 1.25:1.00).